Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John Craig is active.

Publication


Featured researches published by John Craig.


Malaria Journal | 2003

The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids

David C. Warhurst; John Craig; I.S. Adagu; David J. Meyer; Sylvia Y Lee

BackgroundThe 8-amino and 9-hydroxy substituents of antimalarial cinchona alkaloids have the erythro orientation while their inactive 9-epimers are threo. From the X-ray structures a 90° difference in torsion angle between the N1-H1 and C9-O12 bonds in the two series is believed to be important. In order to kill the malaria parasite, alkaloids must cross the erythrocyte and parasite membranes to accumulate in the acid digestive vacuole where they prevent detoxication of haematin produced during haemoglobin breakdown.MethodsIonization constants, octanol/water distribution and haematin interaction are examined for eight alkaloids to explain the influence of small structural differences on activity.ResultsErythro isomers have a high distribution ratio of 55:1 from plasma to the erythrocyte membrane, while for the more basic threo epimers this is only 4.5:1. This gives an increased transfer rate of the erythro drugs into the erythrocyte and thence into the parasite vacuole where their favourable conformation allows interaction with haematin, inhibiting its dimerization strongly (90 ± 7%) and thereby killing the parasite. The threo compounds not only enter more slowly but are then severely restricted from binding to haematin by the gauche alignment of their N1-H1 and C9-O12 bonds. Confirmatory molecular models allowed measurement of angles and bond lengths and computation of the electronic spectrum of a quinine-haematin complex.ConclusionDifferences in the antiplasmodial activity of the erythro and threo cinchona alkaloids may therefore be attributed to the cumulative effects of lipid/aqueous distribution ratio and drug-haematin interaction. Possible insights into the mechanism of chloroquine-resistance are discussed.


The Lancet | 2002

Lysosomes and drug resistance in malaria

David C. Warhurst; John Craig; I.S. Adagu

It is now clear that drugs must be designed that will simultaneously block the integral lysosomal membrane protein (PfCRT)-resistance mechanism and attack the haematin target. That these are not contradictory aims is shown by the relative success of amodiaquine mefloquine and the artemisinins. X-ray crystallography of drug-haematin interaction has not yet been reported and together with more functional studies and structural analysis of PfCRT should be urgently pursued to give a template for much needed new drugs. Haematin remains a key target for antimalarial drug design. Meanwhile in developing countries attempts must continue with the help of international agencies to solve the problems related to cash and infrastructure of access to treatment. (excerpt)


Australian Journal of Chemistry | 1978

The absolute configuration of cryptopleurine and tylocrebrine

E. Gellert; Richard Rudzats; John Craig; Sushil K. Roy; Ronald W. Woodard

The absolute configurations of cryptopleurine and (-)-tylocrebrine have been established as R and S respectively by comparison of their optical rotatory dispersion and circular dichroism spectra with those of tylophorine.


PLOS ONE | 2016

Influence of LAR and VAR on Para-Aminopyridine Antimalarials Targetting Haematin in Chloroquine-Resistance

David C. Warhurst; John Craig; K. Saki Raheem

Antimalarial chloroquine (CQ) prevents haematin detoxication when CQ-base concentrates in the acidic digestive vacuole through protonation of its p-aminopyridine (pAP) basic aromatic nitrogen and sidechain diethyl-N. CQ export through the variant vacuolar membrane export channel, PFCRT, causes CQ-resistance in Plasmodium falciparum but 3-methyl CQ (sontochin SC), des-ethyl amodiaquine (DAQ) and bis 4-aminoquinoline piperaquine (PQ) are still active. This is determined by changes in drug accumulation ratios in parasite lipid (LAR) and in vacuolar water (VAR). Higher LAR may facilitate drug binding to and blocking PFCRT and also aid haematin in lipid to bind drug. LAR for CQ is only 8.3; VAR is 143,482. More hydrophobic SC has LAR 143; VAR remains 68,523. Similarly DAQ with a phenol substituent has LAR of 40.8, with VAR 89,366. In PQ, basicity of each pAP is reduced by distal piperazine N, allowing very high LAR of 973,492, retaining VAR of 104,378. In another bis quinoline, dichlorquinazine (DCQ), also active but clinically unsatisfactory, each pAP retains basicity, being insulated by a 2-carbon chain from a proximal nitrogen of the single linking piperazine. While LAR of 15,488 is still high, the lowest estimate of VAR approaches 4.9 million. DCQ may be expected to be very highly lysosomotropic and therefore potentially hepatotoxic. In 11 pAP antimalarials a quadratic relationship between logLAR and logResistance Index (RI) was confirmed, while log (LAR/VAR) vs logRI for 12 was linear. Both might be used to predict the utility of structural modifications.


Cancer Research | 1981

Cholesterol and Cholesterol Epoxides in Nipple Aspirates of Human Breast Fluid

Nicholas L. Petrakis; Larry D. Gruenke; John Craig


Biochemical Pharmacology | 2007

Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum: Role of β-haematin inhibition and drug concentration in vacuolar water- and lipid-phases

David C. Warhurst; John Craig; I.S. Adagu; R. Kiplin Guy; Peter B. Madrid; Quinton L. Fivelman


Cancer Research | 1987

Breast Fluid Cholesterol and Cholesterol Epoxides: Relationship to Breast Cancer Risk Factors and Other Characteristics

Larry D. Gruenke; Margaret Wrensch; Nicholas L. Petrakis; Rei Miike; Virginia L. Ernster; John Craig


Cancer Research | 1989

Breast Fluid Cholesterol and Cholesterol β-Epoxide Concentrations in Women with Benign Breast Disease

Margaret Wrensch; Nicholas L. Petrakis; Larry D. Gruenke; Rei Miike; Virginia L. Ernster; Eileen B. King; Walter W. Hauck; John Craig; William H. Goodson


Anesthesiology | 1985

Placental Transfer of Ephedrine Does Not Affect Neonatal Outcome

Samuel C. Hughes; Major Michael G. Ward; Gershon Levinson; Sol M. Shnider; Richard G. Wricht; Larry D. Gruenke; John Craig


Journal of Antimicrobial Chemotherapy | 2003

Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties

David C. Warhurst; Jonathan C. P. Steele; I.S. Adagu; John Craig; Christopher Cullander

Collaboration


Dive into the John Craig's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rei Miike

University of California

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge